NDLI: Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience.

Please wait, while we are loading the content...

Year: 2017 Volume: 33

Year: 2016 Volume: 32

Year: 2015 Volume: 31

Year: 2014 Volume: 30

Year: 2013 Volume: 29

Year: 2012 Volume: 28

Year: 2011 Volume: 27

Year: 2010 Volume: 26

Year: 2009 Volume: 25

Year: 2008 Volume: 24

Year: 2008 Volume: 24 Issue: 12

Year: 2008 Volume: 24 Issue: 11

Year: 2008 Volume: 24 Issue: 10

Efficacy and tolerance of a hydrocolloid dressing containing hyaluronic acid for the treatment of leg ulcers of venous or mixed origin.

Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database.

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects.

Usability of a pre-filled insulin injection device in a 3-month observational survey of everyday clinical practice in Australia.

Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey.

Hemoglobin levels that trigger erythropoiesis-stimulating agent treatment decisions for cancer-associated anemia--examination of practice in Germany.

Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice.

Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect.

The effect of a nicotine patch on cigarette craving over the course of the day: results from two randomized clinical trials.

Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants.

Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk.

Surveillance study of the susceptibility of Haemophilus influenzae to various antibacterial agents in Europe and Canada.

Costs of skin and skin structure infections due to Staphylococcus aureus: an analysis of managed-care claims.

Post-fracture management of patients with hip fracture: a perspective.

Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience.

Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study.

Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension.

Biosimilars: opinion of an expert panel in the Middle East.

Economic evaluation of medication, laser trabeculoplasty and filtering surgeries in treating patients with glaucoma in the US.

Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study.

A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.

Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia.

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.

Cost-effectiveness of licensed treatment options for restless legs syndrome in the UK and Sweden.

Review of the pharmaceutical properties and clinical effects of the topical NSAID formulation, diclofenac epolamine.

Cost-effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery: the evolving application of health economic modelling over 20 years.

Year: 2008 Volume: 24 Issue: 9

Year: 2008 Volume: 24 Issue: 8

Year: 2008 Volume: 24 Issue: 7

Year: 2008 Volume: 24 Issue: 6

Year: 2008 Volume: 24 Issue: 5

Year: 2008 Volume: 24 Issue: 4

Year: 2008 Volume: 24 Issue: 3

Year: 2008 Volume: 24 Issue: 2

Year: 2007 Volume: 23

Year: 2006 Volume: 22

Year: 1983 Volume: 8

Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Willke, Richard J. Zhou, Steve Vogel, Robert A.
Description	Country affiliation: United States Author Affiliation: Willke RJ ( Global Outcomes Research, Pfizer Inc, Peapack, NJ 07977, USA. richard.j.willke@pfizer.com)
Abstract	OBJECTIVE: Recent clinical trials and observational studies have suggested that reduction in low-density lipoprotein cholesterol (LDL-C) does not account for all differences among statins' effects on cardiovascular (CV) events, but that these effects may vary with time. Using a large US managed-care claims data set for 2002-2005, we assessed whether a difference in the rate of inpatient CV event rates could be observed between new atorvastatin and simvastatin users taking doses with comparable LDL-C-lowering potency, when prior risk factors are controlled and varying observation periods are employed. RESEARCH DESIGN AND METHODS: Eligible patients had a 6-month period of no statin use prior to the initial statin prescription, an initial statin dosage of either 20 or 40 mg of simvastatin or 10 or 20 mg of atorvastatin (the most commonly used doses of both drugs), a 0 to 3-month 'qualifying period' after the first prescription to allow for varying minimum lengths of statin use, and no statin switches. In the primary analysis, patients were observed until an event or significant non-adherence occurred, up to 3.5 years; in secondary analyses, maximum 3-month, 6-month and 1-year observation periods were used. The primary endpoint was the first inpatient admission due to a CV event after the end of the qualifying period; multivariate Cox regression analysis controlled for a variety of demographic and CV risk characteristics and statin type. RESULTS: At baseline, simvastatin users had significantly higher observed risk factors and higher subsequent, unadjusted CV event rates. In the primary Cox regression analyses, the CV event hazard rates for atorvastatin ranged from 0.899 (1-month qualifying period, p = 0.027) to 0.936 (3-month qualifying period, p = 0.33) versus simvastatin. Cox-based hazard rates for atorvastatin during 3-month to 1-year observation periods ranged from 0.908 to 0.915 for the 0-day qualifying period and from 0.851 to 0.884 for the 1-month qualifying period cohort (all p < 0.05); rates for the 3-month qualifying period cohort remained non-significant. LIMITATIONS: Since this was not a prospective randomized study, there is the potential for unobserved risk factors to be responsible for some or all of the differences observed. CONCLUSIONS: These results indicate an association between atorvastatin use and lower CV event rates, particularly in the first year of use, when observable risk factor differences are controlled. The implied absolute risk reduction of 2-3 events per 1000 patients per year may be considered clinically significant when viewed relative to major clinical trial results.
File Format	HTM / HTML
ISSN	03007995
Issue Number	10
Volume Number	24
e-ISSN	14734877
Journal	Current Medical Research and Opinion
Language	English
Publisher	Taylor & Francis
Publisher Date	2008-10-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Medicine Anticholesteremic Agents Administration & Dosage Cardiovascular Diseases Prevention & Control Heptanoic Acids Pyrroles Simvastatin Adult Aged Aged, 80 And Over Adverse Effects Atorvastatin Calcium Epidemiology Clinical Trials As Topic Female Humans Insurance Claim Review Male Middle Aged Retrospective Studies Risk Factors Time Factors Journal Article
Content Type	Text
Resource Type	Article
Subject	Medicine

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in